GO:0035458 cellular response to interferon-beta: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035458 describes how a single cell changes its state or activity after encountering interferon-beta (IFN-beta), a type I interferon.
• The response begins when IFN-beta binds the IFNAR1/IFNAR2 receptor and triggers JAK-STAT signaling, leading to hundreds of interferon-stimulated genes.
• IFN-beta is produced during innate immune sensing of cytosolic DNA and mRNA vaccines, linking this GO term to antiviral and antitumor immunity.
• Dysregulated cellular responses to IFN-beta contribute to autoimmune diseases such as lupus and multiple sclerosis, and to melanoma biology.
• Genome-editing models (knockout, point mutation, knock-in, overexpression) are essential to test which genes causally drive the IFN-beta response.
• CRISPR library screening and bioinformatics can map the full genetic network of GO:0035458 in a single experiment.
Description
GO:0035458, cellular response to interferon-beta, is a Gene Ontology biological process that captures every change in a cell's state or activity caused by an interferon-beta (IFN-beta) stimulus. IFN-beta is a type I interferon, a cytokine rapidly induced after innate immune sensing of cytosolic DNA or mRNA vaccines, and it acts on cells through the type I interferon receptor. Because the response is cell-intrinsic, it is studied in many systems, from pluripotent human cells to melanoma lines and macrophages.
cellular response to interferon-beta At A Glance
| GO ID | GO:0035458 |
|---|---|
| GO term | cellular response to interferon-beta |
| Ontology | biological_process |
| Synonym | cellular response to beta-1 interferon; cellular response to fiblaferon; cellular response to fibroblast interferon |
| Major function | Cell-intrinsic signal transduction and gene expression changes triggered by IFN-beta |
| Stimulus | Interferon-beta, a type I interferon cytokine |
| Key receptor | IFNAR1 / IFNAR2 heterodimeric type I interferon receptor |
| Downstream signature | Induction of interferon-stimulated genes (ISGs) via JAK-STAT signaling |
| Representative contexts | Antiviral immunity, antitumor immunity, autoimmunity, vaccine responses |
What Is GO:0035458?
In plain terms, GO:0035458 is the set of events that happen inside a cell after it detects interferon-beta. The QuickGO definition states that it is any process that results in a change in state or activity of a cell (movement, secretion, enzyme production, gene expression, etc.) as a result of an interferon-beta stimulus, where interferon-beta is a type I interferon. Synonyms include cellular response to beta-1 interferon, cellular response to fiblaferon, and cellular response to fibroblast interferon.
Why Is cellular response to interferon-beta Important in Cell Biology?
The cellular response to interferon-beta is a central node of innate and adaptive immunity, and it is one of the most frequently perturbed pathways in human disease. It is required for antitumor immunity after radiation, is induced at mRNA vaccine injection sites, and shapes autoimmune pathology in lupus and multiple sclerosis. Because the same pathway can be protective or pathogenic depending on context, precise experimental models are needed to dissect which genes causally drive each outcome.
• Mediates antiviral and antitumor immunity downstream of cytosolic DNA sensing.
• Is induced locally after mRNA vaccination and supports cellular immunity.
• Drives interferon-stimulated gene programs that restrict pathogen replication.
• Contributes to autoimmune pathology, including lupus and multiple sclerosis.
• Modulates melanoma cell behavior and is explored as a gene-transfer therapeutic.
• Is attenuated in pluripotent human cells, revealing cell-state-specific regulation.
• Interacts with DNA damage and senescence pathways through MRE11 and TREX1.
• Is modulated by vitamin D in multiple sclerosis, showing environmental regulation.
• Is a major source of biomarkers and drug targets in immuno-oncology.
• Provides a tractable model for CRISPR screens of innate immune signaling.
What Happens During cellular response to interferon-beta?
IFN-beta production and sensing
In simple terms: First, the cell or its neighbors make interferon-beta and release it.
IFN-beta production is triggered by innate immune sensing of cytosolic DNA, which is STING-dependent, and by mRNA vaccines at the injection site. This step establishes the ligand that initiates GO:0035458 in responding cells.
Receptor binding and JAK-STAT activation
In simple terms: Interferon-beta docks onto a receptor and switches on signaling enzymes.
IFN-beta binds the type I interferon receptor IFNAR1/IFNAR2, activating JAK kinases and STAT transcription factors. This canonical cascade is the core of the cellular response and leads to transcriptional reprogramming.
Interferon-stimulated gene expression
In simple terms: The cell turns on hundreds of antiviral and immune genes.
Activated STAT complexes drive expression of interferon-stimulated genes (ISGs), which change the cell's state and activity. This gene-expression output is the measurable signature of GO:0035458 in transcriptomic experiments.
Crosstalk with DNA damage and senescence
In simple terms: Interferon-beta signaling talks to the cell's DNA-repair machinery.
MRE11 and TREX1 coordinate replication stress and interferon signaling, linking GO:0035458 to senescence and genome stability. This crosstalk means the response is not isolated but integrated with stress pathways.
Cell-type-specific tuning
In simple terms: Different cells respond to interferon-beta with different strength.
Pluripotent human cells show an attenuated response to interferon-beta, whereas macrophages and melanoma cells mount distinct programs. This context dependence is a key reason to study GO:0035458 in multiple model systems.
Key Genes Involved in GO:0035458 cellular response to interferon-beta
The following genes and proteins are experimentally implicated in the cellular response to interferon-beta and are commonly used as readouts or perturbation targets.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNB1 | Encodes interferon-beta, the ligand that initiates GO:0035458 | Central to antiviral and antitumor immunity studies |
| IFNAR1 | Type I interferon receptor subunit | Required for IFN-beta signal transduction |
| IFNAR2 | Type I interferon receptor subunit | Forms heterodimer with IFNAR1 to bind IFN-beta |
| JAK1 | Janus kinase downstream of IFNAR | Phosphorylates STAT proteins after IFN-beta stimulation |
| STAT1 | Transcription factor driving ISG expression | Key readout of cellular response to IFN-beta |
| STAT2 | Partner of STAT1 in ISGF3 complex | Required for interferon-stimulated gene transcription |
| IRF9 | Component of ISGF3 transcription complex | Mediates ISG induction downstream of IFN-beta |
| STING1 | Cytosolic DNA sensor adaptor upstream of IFN-beta | Links radiation-induced antitumor immunity to IFN-beta |
| MRE11 | DNA repair factor coordinating replication stress and interferon signaling | Connects genome stability to GO:0035458 |
| TREX1 | Exonuclease controlling cytosolic DNA and interferon signaling | Regulates senescence-associated interferon response |
| VDR | Vitamin D receptor modulating IFN-beta responses | Explains vitamin D effects in multiple sclerosis |
| TLR4 | Toll-like receptor contributing to macrophage IFN-beta response | Model for innate immune crosstalk |
| MDSC markers | Myeloid-derived suppressor cell program producing IFN-beta | Linked to lupus pathogenesis |
| ISG15 | Interferon-stimulated gene product | Common readout of IFN-beta pathway activation |
| MX1 | Interferon-induced antiviral effector | Biomarker of cellular response to IFN-beta |
| OAS1 | Interferon-induced antiviral enzyme | Downstream effector of GO:0035458 |
| IFIT1 | Interferon-induced protein with antiviral activity | Readout of ISG program |
| CXCL10 | Interferon-inducible chemokine | Links IFN-beta response to immune cell recruitment |
How Is cellular response to interferon-beta Regulated?
The cellular response to interferon-beta is regulated at multiple levels. Vitamin D enhances responses to interferon-beta in multiple sclerosis, showing that the pathway is modulated by nuclear receptor signaling. MRE11 and TREX1 coordinate replication stress with interferon signaling, providing a checkpoint-like control over the response. In pluripotent human cells, the response is attenuated, indicating developmental or cell-state regulation. Macrophage responses to lipopolysaccharide also involve interferon-beta, showing integration with TLR4 signaling.
cellular response to interferon-beta and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| STING1 | Antitumor immunity after radiation | STING1 knockout tumor cells |
| IFNB1 | Lupus and autoimmunity | IFNB1 overexpression in myeloid cells |
| VDR | Multiple sclerosis | VDR knockout T cells treated with IFN-beta |
| MRE11 | Senescence and genome instability | MRE11 point-mutation knock-in cells |
| TREX1 | Interferonopathy and senescence | TREX1 knockout fibroblasts |
Cancer and antitumor immunity
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity, placing GO:0035458 at the center of immunotherapy responses. Human melanoma cell lines respond to interferon-beta gene transfer mediated by a modified adenoviral vector, supporting therapeutic exploration.
Autoimmune disease
Myeloid-derived suppressor cell-derived interferon-beta promotes T follicular helper cell responses and exacerbates lupus development, showing a pathogenic role for this pathway. In multiple sclerosis, vitamin D enhances responses to interferon-beta, linking environmental factors to disease modulation.
Senescence and genome stability
MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling, connecting GO:0035458 to aging-related phenotypes. This suggests that interferon-beta responses can be a consequence of accumulated DNA damage.
Vaccination and innate immunity
Innate immune responses against mRNA vaccines promote cellular immunity through IFN-beta at the injection site, demonstrating that GO:0035458 is a key mediator of vaccine immunogenicity. Macrophage responses to TLR4 agonists also depend on interferon-beta, broadening the disease relevance.
From cellular response to interferon-beta-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for IFN-beta-induced ISG expression? | CRISPR knockout in a responsive cell line |
| Does a disease-associated variant alter IFN-beta signaling? | Point-mutation knock-in at the endogenous locus |
| Where does a signaling protein localize after IFN-beta stimulation? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a gene amplify the IFN-beta response? | Stable overexpression cell line |
| Which genes globally regulate GO:0035458? | Genome-wide CRISPR library screening |
| How do pluripotent cells differ in IFN-beta response? | Knockout or overexpression in human pluripotent cells |
How to Study the cellular response to interferon-beta Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Interferon-stimulated gene expression | Profiling GO:0035458 output |
| CRISPR knockout screen | Genes required for IFN-beta response | Pathway discovery |
| Phospho-Western blot | JAK-STAT activation | Validation of signaling |
| ELISA | IFN-beta protein secretion | Ligand production measurement |
| Flow cytometry | Immune cell activation and ISG markers | Vaccine and autoimmune studies |
| Proteomics | Global protein changes after IFN-beta | Mechanistic profiling |
| Reporter assays | ISG promoter activity | High-throughput screening |
| Animal tumor models | Antitumor immunity | Radiation and immunotherapy studies |
Transcriptomic profiling of ISGs
RNA-seq after IFN-beta stimulation quantifies the interferon-stimulated gene program that defines GO:0035458. This approach has been used to characterize responses in melanoma cells and after mRNA vaccination.
CRISPR screening for pathway regulators
Genome-wide CRISPR knockout or activation screens identify genes that enhance or suppress the cellular response to interferon-beta. Screens have been applied to innate immune signaling and senescence-related interferon responses.
Protein and phospho-signaling analysis
Western blotting and phospho-proteomics measure JAK-STAT activation after IFN-beta treatment. These methods are standard for validating receptor-proximal events in GO:0035458.
Functional immune assays
Antiviral, antitumor, and T cell activation assays link molecular changes to phenotype. Examples include radiation-induced antitumor immunity and lupus T follicular helper cell responses.
How CRISPR Can Be Used to Study GO:0035458 cellular response to interferon-beta
Knockout
CRISPR knockout of candidate genes such as IFNAR1, STAT1, or STING1 tests whether they are required for the cellular response to interferon-beta. Knockout models are widely used to validate innate immune signaling.
Point Mutation
Point-mutation knock-in can model disease-associated variants in genes like VDR or MRE11 and measure their effect on IFN-beta responses. This approach connects genotype to pathway function.
Knock-in
Tagged knock-in of signaling proteins allows live-cell imaging and proteomic pull-down after IFN-beta stimulation. This is useful for tracking STAT or receptor dynamics.
Overexpression
Overexpression of IFNB1 or downstream effectors amplifies the response and can model autoimmune or antitumor contexts. Melanoma gene-transfer studies illustrate this strategy.
How EDITGENE Supports cellular response to interferon-beta Research
Researchers studying cellular response to interferon-beta-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with it. EDITGENE provides the full spectrum of CRISPR cell models and screening services required to move from correlation to causation.
Contact EDITGENE today to design your custom CRISPR model for cellular response to interferon-beta research.
Frequently Asked Questions About cellular response to interferon-beta
What is GO:0035458 cellular response to interferon-beta?
It is a Gene Ontology biological process describing any change in a cell's state or activity caused by interferon-beta, a type I interferon.
What genes are involved in cellular response to interferon-beta?
Key genes include IFNB1, IFNAR1, IFNAR2, JAK1, STAT1, STAT2, IRF9, STING1, MRE11, TREX1, and VDR.
How does interferon-beta signal inside a cell?
It binds the IFNAR1/IFNAR2 receptor, activates JAK-STAT signaling, and induces interferon-stimulated genes.
Why is cellular response to interferon-beta important in cancer?
STING-dependent DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity, and melanoma cells respond to IFN-beta gene transfer.
Is interferon-beta involved in autoimmune diseases?
Yes, myeloid-derived suppressor cell-derived IFN-beta exacerbates lupus, and vitamin D enhances IFN-beta responses in multiple sclerosis.
How is cellular response to interferon-beta studied experimentally?
Common methods include RNA-seq, CRISPR screens, phospho-Western blotting, ELISA, and flow cytometry.
What is the difference between interferon-beta and other type I interferons?
Interferon-beta is a type I interferon that signals through the same IFNAR receptor but is encoded by IFNB1 and has distinct production triggers.
Can CRISPR knockout help study interferon-beta signaling?
Yes, knockout of IFNAR1, STAT1, or STING1 tests whether these genes are required for the response.
What diseases are linked to interferon-beta pathway dysregulation?
Cancer, lupus, multiple sclerosis, and senescence-related disorders are linked to this pathway.
What services does EDITGENE offer for interferon-beta research?
EDITGENE offers knockout, point-mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics.
Conclusion
GO:0035458 cellular response to interferon-beta is a central biological process that converts an innate immune cytokine signal into broad changes in cell state and gene expression. Its roles in antitumor immunity, autoimmunity, vaccination, and senescence make it a high-value target for mechanistic and translational research.
References
- 1. Deng L et al.. 2014. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.. Immunity 41(5):843-52 PMID: 25517616
- 2. Kim S et al.. 2024. Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site.. Nat Commun 15(1):7226 PMID: 39191748
- 3. David TIP et al.. 2020. Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.. Sci Rep 10(1):17893 PMID: 33087767
- 4. Rui K et al.. 2026. Myeloid-Derived Suppressor Cell-Derived Interferon-β Promotes T Follicular Helper Cell Response and Exacerbates Lupus Development.. Arthritis Rheumatol 78(5):1088-1101 PMID: 41312596
- 5. Feng X et al.. 2019. Vitamin D enhances responses to interferon-β in MS.. Neurol Neuroimmunol Neuroinflamm 6(6):e622 PMID: 31582399
- 6. Técher H et al.. 2024. MRE11 and TREX1 control senescence by coordinating replication stress and interferon signaling.. Nat Commun 15(1):5423 PMID: 38926338
- 7. Hong XX et al.. 2013. Innate immunity in pluripotent human cells: attenuated response to interferon-β.. J Biol Chem 288(22):16196-205 PMID: 23599426
- 8. Thomas KE et al.. 2006. Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide.. J Biol Chem 281(41):31119-30 PMID: 16912041
